Battle lines are being drawn up in metastatic castration-resistant prostate cancer (mCRPC), with AstraZeneca and Merck & Co’s market-leading PARP inhibitor Lynparza firmly in th ...

The new analysis – presented at the San Antonio Breast Cancer Symposium (SABCS) – reveals that 87.5% of patients treated with Lynparza were alive at six years compared to 83.2% in the ...